Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Aptamer Group reports 41% revenue growth and new licensing deals

Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise...

GSK raises 2025 guidance after strong Q2 performance

GSK reported Q2 2025 turnover of £8.0bn, up 6% CER, with strong growth in Specialty Medicines (+15%) and Vaccines (+9%). Core EPS rose 15% to 46.5p...

One Health Group a “buy” in This is Money Midas Share Tips

Analysts at Midas Share Tips described the company as well-managed and well-positioned to benefit from ongoing NHS reliance on external capacity...

GSK and Hengrui Pharma to develop up to 12 new medicine programmes

GSK plc has entered agreements with Hengrui Pharma to develop up to 12 innovative medicines, including an exclusive worldwide licence (ex‑China) for HRS‑9821, a potential best‑in‑class PDE3/4 inhibitor for COPD, for $500 million in upfront fees and up to $12 billion in milestone payments...

When buildings become health’s best asset

Investors are discovering that medical properties offer a unique blend of resilience and growth potential in unpredictable markets...

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

Oxford Nanopore delivers 25% revenue growth in H1 2025

Revenue rose to £105 million, up 28% constant currency, driven by PromethION growth of 59% and strong gains in Applied markets. Adjusted EBITDA loss narrowed, cash stood at £337 million and full‑year guidance remains on track...

Aptamer Group extends Unilever collaboration for deodorant Optimers

Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials...

GSK’s Arexvy FDA review accepted for adults 18-49 at increased risk

The US FDA has accepted GSK’s application to extend Arexvy to adults aged 18-49 at increased risk of severe RSV infection, supported by positive Phase IIIb data; a decision is expected in H1 2026...

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...

Aptamer Group raises £2.0 million in share placing

Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery...

One Health Group granted planning approval for Scunthorpe surgical hub

One Health Group plc has secured planning permission for its first surgical hub in Scunthorpe, Lincolnshire, set to open in late summer 2026...

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...

Aptamer Group raises £2m to fund growth

Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount...

One Health Group: Record Growth and New Surgical Hub Development (LON:OHGR)

One Health Group CEO Adam Binns discusses the company’s record growth and strategic future, highlighting a 28% increase in NHS patient referrals, the successful AIM listing raising £7.8 million, and plans to open their first surgical hub by next summer..

NIOX Group a ‘Buy’ with Dependable Growth and Cashflow, Singer (LON: NIOX) 

NIOX continues to capitalise on both clinical and research markets, delivering consistent growth and strengthening its cash position...

One Health reshaping surgical care across northern England

One Health Group is steadily extending NHS‑backed elective care in northern England, underpinned by a 23% revenue surge and a funded surgical hub...

Aptamer advances liver fibrosis therapy with targeted gene delivery

Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells...

One Health Group Record Patient Growth and a Strategic Leap with New Surgical Hubs (Video)

One Health Group CEO Adam Binns shares how record NHS patient numbers, a successful AIM listing, and the upcoming launch of their first surgical hub are fuelling the company’s growth—and why this is just the beginning...
Search

Funds

Health

Aptamer Group reports 41% revenue growth and new licensing deals

Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise...

GSK raises 2025 guidance after strong Q2 performance

GSK reported Q2 2025 turnover of £8.0bn, up 6% CER, with strong growth in Specialty Medicines (+15%) and Vaccines (+9%). Core EPS rose 15% to 46.5p...

One Health Group a “buy” in This is Money Midas Share Tips

Analysts at Midas Share Tips described the company as well-managed and well-positioned to benefit from ongoing NHS reliance on external capacity...

GSK and Hengrui Pharma to develop up to 12 new medicine programmes

GSK plc has entered agreements with Hengrui Pharma to develop up to 12 innovative medicines, including an exclusive worldwide licence (ex‑China) for HRS‑9821, a potential best‑in‑class PDE3/4 inhibitor for COPD, for $500 million in upfront fees and up to $12 billion in milestone payments...

When buildings become health’s best asset

Investors are discovering that medical properties offer a unique blend of resilience and growth potential in unpredictable markets...

AstraZeneca to invest $50bn in the US, new Virginia manufacturing site planned

AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

Oxford Nanopore delivers 25% revenue growth in H1 2025

Revenue rose to £105 million, up 28% constant currency, driven by PromethION growth of 59% and strong gains in Applied markets. Adjusted EBITDA loss narrowed, cash stood at £337 million and full‑year guidance remains on track...

Aptamer Group extends Unilever collaboration for deodorant Optimers

Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials...

GSK’s Arexvy FDA review accepted for adults 18-49 at increased risk

The US FDA has accepted GSK’s application to extend Arexvy to adults aged 18-49 at increased risk of severe RSV infection, supported by positive Phase IIIb data; a decision is expected in H1 2026...

AstraZeneca’s Baxdrostat meets Phase III endpoints in Hypertension trial

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...

Aptamer Group raises £2.0 million in share placing

Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery...

One Health Group granted planning approval for Scunthorpe surgical hub

One Health Group plc has secured planning permission for its first surgical hub in Scunthorpe, Lincolnshire, set to open in late summer 2026...

AstraZeneca’s Imfinzi approved in EU for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...

Aptamer Group raises £2m to fund growth

Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount...

One Health Group: Record Growth and New Surgical Hub Development (LON:OHGR)

One Health Group CEO Adam Binns discusses the company’s record growth and strategic future, highlighting a 28% increase in NHS patient referrals, the successful AIM listing raising £7.8 million, and plans to open their first surgical hub by next summer..

NIOX Group a ‘Buy’ with Dependable Growth and Cashflow, Singer (LON: NIOX) 

NIOX continues to capitalise on both clinical and research markets, delivering consistent growth and strengthening its cash position...

One Health reshaping surgical care across northern England

One Health Group is steadily extending NHS‑backed elective care in northern England, underpinned by a 23% revenue surge and a funded surgical hub...

Aptamer advances liver fibrosis therapy with targeted gene delivery

Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells...

One Health Group Record Patient Growth and a Strategic Leap with New Surgical Hubs (Video)

One Health Group CEO Adam Binns shares how record NHS patient numbers, a successful AIM listing, and the upcoming launch of their first surgical hub are fuelling the company’s growth—and why this is just the beginning...
Search

Funds

Health

FTSE 100

Funds